TITLE

Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer

AUTHOR(S)
Somlo, G.; Simpson, J.F.; Frankel, P.; Chow, W.; Leong, L.; Margolin, K.; Jr., R. Morgan; Raschko, J.; Shibata, S.; Forman, S.; Kogut, N.; McNamara, M.; Molina, A.; Somlo, E.; Doroshow, J.H.
PUB. DATE
July 2002
SOURCE
British Journal of Cancer;7/29/2002, Vol. 87 Issue 3, p281
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Identifies the predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer. Survival rate; p53 protein expression; Estrogen-progesterone receptor status; Stage of the disease; Mitotic index.
ACCESSION #
8649741

 

Related Articles

  • Estrogen-dependent and independent activation of the P1 promoter of the p53 gene in transiently transfected breast cancer cells. Hurd, Cliff; Dinda, Sumi; Khattree, Nidhi; Moudgil, V K // Oncogene;1/28/99, Vol. 18 Issue 4, p1067 

    Loss of p53 function by mutational inactivation is the most common marker of the cancerous phenotype. Previous studies from our laboratory have demonstrated 17 β estradiol (E2) induction of p53 protein expression in breast cancer cells. Although direct effects of E2 on the expression of p53...

  • Correlation of ER, PR, HER- 2 and P53 Immunoreactions with Clinico-Pathological Features in Breast Cancer. Abdollahi, Alireza; Sheikhbahaei, Sara; Safinejad, Somaye; Jahanzad, Issa // Iranian Journal of Pathology;Summer2013, Vol. 8 Issue 3, p147 

    Background and Objectives: The most prevalent malignancy among women is known to be breast cancer (BC). Several factors contribute to determining tumor prognosis and treatment strategies. In this study, the frequency and relevance of these factors are discussed. Materials and Methods: This...

  • Loss of p53-immunostaining intensity in breast cancer. Henson, Donald E. // JNCI: Journal of the National Cancer Institute;08/07/96, Vol. 88 Issue 15, p1015 

    Editorial. Comments on the impact of lost immunostaining intensity of the P53 antioncogene in treating breast cancer. Amount of immunoreactivity lost after two weeks storage on unstained glass slides; Chemicals and stain preparation procedures suspected for the lost immunostaining capacity of...

  • Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. Jacobs, Timothy W.; Prioleau, John E. // JNCI: Journal of the National Cancer Institute;08/07/96, Vol. 88 Issue 15, p1054 

    Discusses the decrease in the immunostaining properties of the P53 antioncogenes in slides of breast cancer samples. Theories linking environmental storage conditions and slide preparation chemicals to immunostaining loss; Progress of the decline in staining intensity after two weeks.

  • Heterogeneity: Cooperative crosstalk. Seton-Rogers, Sarah // Nature Reviews Cancer;Apr2015, Vol. 15 Issue 4, p198 

    The article discusses the study "Intratumoral Heterogeneity in a p53 Null Mouse Model of Human Breast Cancer" by researcher M. Zhang and colleagues and published win the journal "Cancer Discovery" which discusses factors promoting tumour growth in breast.

  • Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast. Regele, S; Kohlberger, P; Vogl, F D; Böhm, W; Kreienberg, R; Runnebaum, I B // British Journal of Cancer;10/15/99, Vol. 81 Issue 4, p702 

    Five of 43 patients (11.6%) with ductal carcinoma in situ of the breast presented with p53 autoantibodies at diagnosis. Three seropositive patients demonstrated tumour sizes of ≤ 5 mm. There was no association of p53 autoantibody status with age, clinical presentation, histological...

  • Pathology/cytology.  // Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS75 

    Presents an abstract of the research manuscript `P53, ErbB2 and TAG-72 expression in the spectrum of ductal carcinoma in situ of the breast classified by the Van Nuy's System,' by R. Kanthan et al.

  • Estrogens, regulation of p53 and breast cancer risk: a balancing act. Jerry, D. Joseph; Dunphy, Karen A.; Hagen, Mary J. // Cellular & Molecular Life Sciences;Apr2010, Vol. 67 Issue 7, p1017 

    The paradoxical effects of ovarian hormones in both the promotion and prevention of breast cancer have been debated for over 30 years. Genetic studies have demonstrated that ovarian hormones act through NF-κB to stimulate proliferation and ductal elongation, whereas the p53 tumor suppressor...

  • A p53-independent role of Mdm2 in estrogenmediated activation of breast cancer cell proliferation. Brekman, Angelika; Singh, Kathryn E.; Polotskaia, Alla; Kundu, Nandini; Bargonetti, Jill // Breast Cancer Research;2012, Vol. 13 Issue 1, p1 

    Introduction: Estrogen receptor positive breast cancers often have high levels of Mdm2. We investigated if estrogen signaling in such breast cancers occurred through an Mdm2 mediated pathway with subsequent inactivation of p53. Methods: We examined the effect of long-term 17b-estradiol (E2)...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics